



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 7/04, 5/08, A61K 38/06, 38/08</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/63236</b> <b>(43) International Publication Date:</b> 26 October 2000 (26.10.00)
<b>(21) International Application Number:</b> PCT/US00/10329 <b>(22) International Filing Date:</b> 17 April 2000 (17.04.00)  <b>(30) Priority Data:</b> 60/129,709                      16 April 1999 (16.04.99)                      US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US    60/129,709 (CIP) Filed on    16 April 1999 (16.04.99)  <b>(71) Applicant (for all designated States except US):</b> CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> ASHKAR, Samy [LB/US]; Apartment 606, 12 Stoneholm Street, Boston, MA 02115 (US).  <b>(74) Agents:</b> HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> ADHESION MODULATORY PEPTIDES AND METHODS FOR USE  <b>(57) Abstract</b>  The invention provides methods for modulating cell adhesion. The invention also provides novel adhesion modulatory peptides, substrates coated with such adhesion modulatory peptides and devices for modulation of target cell adhesion.		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece			<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>ML</b>	Mali	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MN</b>	Mongolia	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MR</b>	Mauritania	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MW</b>	Malawi	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>MX</b>	Mexico	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NE</b>	Niger	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NL</b>	Netherlands	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NO</b>	Norway	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>NZ</b>	New Zealand		
<b>CM</b>	Cameroon			<b>PL</b>	Poland		
<b>CN</b>	China	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CU</b>	Cuba	<b>KZ</b>	Kazakstan	<b>RO</b>	Romania		
<b>CZ</b>	Czech Republic	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>DE</b>	Germany	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DK</b>	Denmark	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>EE</b>	Estonia	<b>LR</b>	Liberia	<b>SG</b>	Singapore		

## ADHESION MODULATORY PEPTIDES AND METHODS FOR USE

### Background of the Invention

5                   Adhesive interactions are critical in the regulation of multiple physiological and cellular processes including cell proliferation, differentiation, angiogenesis, inflammation, tissue development, cell survival, programmed cell death, and tumor cell growth and metastasis. Moreover in disease, adhesive function is frequently compromised and results in tissue disorder, aberrant cell migration and  
10                   dysregulation of signaling pathways. Furthermore, regulation of cell adhesive events has broad biomedical implications. For instance, promotion of cell adhesion is desirable, for example, in the seeding of endothelial cells onto vascular grafts, in the stability of medical prostheses, and in promotion of wound healing. Conversely, inhibition of cell adhesion may be of benefit in the treatment of metastasis.

15                   Adhesive events are widely recognized to be important in cell-cell contact as well as in cell interactions between cells and soluble proteins. Moreover, adhesive events are known to involve interactions between substances surrounding the cell (*e.g.*, extracellular matrix molecules, for example fibronectin, vitronectin and laminin) and extracellular adhesion receptors (*e.g.*, integrin receptors). In particular, the  
20                   integrins are a functionally and structurally related group of receptors that interact with a wide variety of ligands including extracellular matrix glycoproteins, complement and other cells and are involved in many physiologically important processes including hemostasis, thrombosis, wound healing, immune and nonimmune defense mechanisms and oncogenic transformation. Hynes, R.O. (1987) *Cell* 48:549-554. Several integrins  
25                   that participate in dynamic cell adhesion bind a tripeptide, arginine-glycine-aspartic acid (RGD), present in their ligand.

                  Cell adhesion is also mediated by certain adhesive ligands to which extracellular adhesion receptors bind. Among such ligands are the glyco-proteins fibronectin, vitronectin and collagen. All three contain the tripeptide sequence arginine-  
30                   glycine-aspartic acid (Arg-Gly-Asp or R-G-D) which appears to function as the primary recognition site for receptors on the surface of cells binding to these molecules. Ruoslahti *et al.* (1987) *Science* 238:491-497.

### **Summary of the Invention**

In view of the importance of promoting cell adhesion or, conversely, for inhibiting adhesion, peptides and compounds suitable for these purposes are desired. In particular, there exists a need for peptides having an amino acid structure that provides the optimum specificity for the receptor of interest.

The present invention satisfies this need and provides related advantages as well. In particular, the present invention features adhesion modulatory peptides which modulate the adhesion of specific cells or cell types based on the adhesion receptors expressed by the specific cell or cell type. The adhesion modulatory peptides are designed to promote and/or enhance the adhesion of specific cells or cell types based on the adhesion receptors expressed by the specific cell or cell type (*e.g.*, the cells receptor expression profile). The present invention features a method of modulating (*e.g.*, enhancing and/or inhibiting) adhesion of a target cell (*e.g.*, endothelial cells, fibroblasts, macrophages, neutrophils and myofibroblasts) to a substrate (*e.g.*, polyvinyl surfaces, gels, collagen, hyaluronic acid, titanium and PGA) which includes providing the cell with an adhesion modulatory peptide-associated substrate such that adhesion of the target cell to the substrate is modulated. The target cells of the present invention can be present in a cell population and/or in a subject (*e.g.*, a human subject).

The present invention also pertains to substrate treated with adhesion modulatory peptides, devices treated with adhesion modulatory peptides and compositions which include the adhesion modulatory peptides of the present invention and a carrier suitable for *in vivo* use.

### **Detailed Description of the Invention**

The present invention pertains to adhesion modulatory peptides which are designed to promote and/or enhance the adhesion of specific cells or cell types based on the adhesion receptors expressed by the specific cell or cell type (*e.g.*, the cells receptor expression profile). One aspect of the present invention features a method of modulating adhesion of a target cell to a substrate which includes providing the target cell with an adhesion modulatory peptide-associated substrate such that adhesion of the target cell to the substrate is modulated. The language “modulates adhesion” or

“modulating adhesion” includes modulating (*e.g.*, stimulating, promoting, enhancing, decreasing or inhibiting) the attachment of a cell to a substrate (*e.g.*, a physical or a molecular substrate). The term “substrate” includes physical materials (*e.g.*, plastic, polyvinyl surfaces, steel, glass, polymers, PGA, metals, for example, titanium) as well as molecular components (*e.g.*, extracellular matrix components, collagen, glycosaminoglycans, for example, hyaluronic acid, chondroitin sulfates and heparan sulfates). Physical materials and/or molecular components can be purified materials or components. Alternatively, physical materials and/or components can be in the form of a composition or biomaterial (*e.g.*, gels). Accordingly, an “adhesion-modulatory peptide” includes a peptide (*e.g.*, at least two amino acid residues joined by a peptide bond or amide bond) which is capable of modulating adhesion or has the ability to modulate (*e.g.*, promote or inhibit) adhesion of a cell to a substrate. Adhesion-modulatory peptides of the invention are at least 3, preferably at least 4, more preferably at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acid residues in length. Adhesion-modulatory peptides can be between 100 and 2500 Da, between 200 and 2000 Da, between 300 and 1500 Da, or between 500 and 1000 Da. Furthermore, the language “adhesion modulatory peptide-associated substrate” includes a combination or union of an adhesion-modulatory peptide of the present invention in association with a substrate, as defined herein.

The term “target cell includes” a cell (*e.g.*, a mammalian cell) which is capable of binding or has the ability to bind to an adhesion-modulatory peptide or adhesion-modulatory peptide associated substrate of the present invention. In one embodiment, a target cell is present within a subject. In another embodiment, a target cell is isolated from a subject (*e.g.*, a human subject). In yet another embodiment, the target cell is present within a cell population. The term “cell population” includes a collection or group including the target cell and at least a second cell type. Cell populations can also include three, four, five, six or more cell types or can include any number of cell types greater than one (*e.g.*, the target cell and additional undefined cell types). Preferred target cells include, but are not limited to endothelial cells, fibroblasts and macrophages. Additional preferred target cells include, but are not limited to neutrophils and myofibroblasts.

In one embodiment, an adhesion modulatory peptide includes a peptide which specifically enhances adhesion of the target cell to a substrate. The language “specifically enhances” or “specific enhancement” includes a preferred or preferential adhesion (*e.g.*, attachment) of the target cell as compared to a second cell or cell type (*e.g.*, a second cell in a cell population or in a subject). In another embodiment, an adhesion modulatory peptide includes a peptide which specifically inhibits adhesion of the target cell. The language “specifically inhibits” or “specific inhibition” includes a preferential inhibition of adhesion (*e.g.*, attachment) of the target cell as compared to a second cell or cell type (*e.g.*, a second cell in a cell population or in a subject). Preferred adhesion modulatory peptides (*e.g.*, peptides which enhance adhesion) include, but are not limited to, endothelial cell adhesion modulatory peptides, fibroblast adhesion modulatory peptides and macrophage adhesion modulatory peptides. Additional preferred adhesion modulatory peptides (*e.g.*, peptides which inhibit adhesion) include, but are not limited to, neutrophil adhesion modulatory peptides or myofibroblast adhesion modulatory peptides. Particularly preferred adhesion modulatory peptides are set forth in Table II.

In one embodiment, an adhesion modulatory molecule of the present invention enhances binding of an adhesion receptor predominantly expressed by the target cell. The language “predominantly expressed” includes adhesion receptors which are more highly expressed on a cell’s surface as compared to other adhesion receptors also expressed on the cell’s surface. Preferably, a “predominantly expresses” adhesion receptor is present at least 1.5 times the level of a second adhesion receptor, preferably at least 2 times the level of a second adhesion receptor, more preferably at least 3 times the level of a second receptor, and more preferably at least 5, 10, 50, 100 or 500 times the level of a second receptor. In another embodiment, an adhesion modulatory molecule inhibits binding of an adhesion receptor predominantly expressed by the target cell. The preferential expression of specific adhesion receptors on the surface of a cell (*e.g.*, on the surface of a target cell) provides for preferential or specific adhesion of a preferred cell type (*i.e.*, the target cell).

Yet another aspect on the invention features contacting a substrate with an adhesion modulatory peptide, forming an adhesion modulatory peptide-associated substrate prior to providing the cell with the substrate. The phrase “contacting” includes

- 5 -

mixing, incubating or coating the substrate with an adhesion-modulatory peptide of the present invention. For example, the adhesion-modulatory peptides of the present invention can be dissolved or solublized in a suitable solution (*e.g.*, an aqueous solution buffered aqueous solution, organic solvent, buffered organic solvent) and coated on a physical substrate (*e.g.*, a polymer, plastic or biomaterial). Solutions or solvents can be aspirated and/or evaporated to result in a coating of the substrate. Alternatively, the peptides can be covalently adhered to a substrate (*e.g.*, *via* a covalent modification and/or covalent linkage) or can be adhered *via* spacer molecules such that steric hindrance of the peptide conformation is diminished or avoided. Spacers, include, but are not limited to aminohexanoic acid, polyglycine, polyamides, polyethylenes, and short functionalized polymers having a carbon backbone (*e.g.*, about 1-12 residues in length). The present invention also pertains to substrate treated with adhesion modulatory peptides, devices (*e.g.*, biomedical devices) treated with adhesion modulatory peptides and compositions which include the adhesion modulatory peptides of the present invention and a carrier suitable for *in vivo* use.

#### *Cell Type Specific Expression of Adhesion Receptors*

As described above, the adhesion-modulatory peptides of the present invention have particularly utility in the attachment or adhesion of specific cells types (*e.g.*, of a target cell within a cell population). The following section sets forth specific adhesion receptors, in particular, integrins, and describes the naturally-occurring ligands for such adhesion receptors/integrins as well as various cell types which express the particular adhesion receptor/integrin.

Alpha1/beta1 is a receptor for collagen-I collagen-IV and laminin (E1 region). It is expressed on activated T-cells, monocytes, melanoma cells and smooth muscle cells. This integrin is also known as VLA-1 (very late activation antigen 1).

Alpha2/beta1 is a receptor for collagen-I to VI, laminin and possibly fibronectin. It is expressed on B and T lymphocytes, platelets, fibroblasts, endothelial cells and melanoma cells. This receptor is also known as VLA-2 (very late activation antigen 2), GPIa-IIa (glycoprotein Ia-IIa on platelets) and ECMRII (extracellular matrix receptor II)

- 6 -

Alpha3/beta1 is a receptor for epiligrin, laminin (E3 fragment), nidogen/entactin, fibronectin and collagen-1. It is expressed on B-lymphocytes, Kidney glomerulus and most cultured cell lines. This integrin is also known as VLA-3 (very late activation antigen 3), VCA-2 (very common antigen 2), ECMRI (extracellular matrix receptor I) and Gapb-3 (galactoprotein b3).

Alpha4/beta1 is a receptor for fibronectin containing the CS-1 region, which is situated within the IIIICS region, and VCAM-1 (vascular cellular adhesion molecule 1). It is present on lymphocytes, monocytes, eosinophils, NK-cells and thymocytes. This integrin plays a role in the invasion of inflamed tissues, and has also been implicated in skeletal myogenesis, neural crest migration and proliferation, lymphocyte maturation and morphogenesis of the placenta and heart. VCAM-1 is an adhesion molecule which is present on cytokine-activated endothelial cells, while fibronectin is part of the extracellular matrix. Alpha4/beta1 is thus involved in both cell-cell and cell-extracellular matrix adhesion. This integrin is also known as VLA-4 (very late activation antigen 4) and LPAM-2 (lymphocyte Peyer's patch HEV adhesion molecule 2 (mouse)).

Alpha5/beta1 is a receptor for fibronectin. It is expressed on Memory-T-cells, monocytes, platelets and fibroblasts. This integrin is also known as VLA-5 (very late activation antigen 5), FNR (fibronectin receptor), GPIc-IIa (glycoprotein Ic-IIa on platelets) and ECMRVI (extracellular matrix receptor VI).

The alpha4/beta7 integrin is a receptor for MadCAM, fibronectin and VCAM-1. This integrin is only found leukocytes which are directed to the Peyer's Patches of the gut. MadCAM which is an addressin, is only found on Peyer's Patch Endothelium. The alpha4/beta7 integrin is also known as (LPAM-1).

The alpha6/beta1 integrin is expressed on platelets, lymphocytes, monocytes, thymocytes and epithelial cells, on which it functions as a laminin receptor for laminin-1, laminin-2 and laminin-4 *in vivo*. It is also a receptor for laminin-5, but not *in vivo*. For laminin-1, the binding site has been localized in the E8 domain of this extracellular matrix molecule. This receptor is also known as VLA-6 (very late activation antigen 6) and GPIc-IIa (glycoprotein Ic-IIa on platelets).



The alpha-6/beta-4 integrin is expressed on different cell-types. It is expressed on immature thymocytes, on squamous epithelia, on subsets of endothelial cells, on Schwann cells and also on fibroblasts in the peripheral nervous system. In stratified epithelia like the skin, alpha-6/beta-4 is concentrated in dense structures which are called hemidesmosomes. These dense structures are involved in the attachment of basal cells to the underlying basement membranes. This is achieved by connection of the intermediate filaments to the extracellular matrix via this integrin. All the other integrins use actin filaments for this purpose instead of intermediate filaments. The ligands for the alpha-6/beta-4 integrin are laminin-1 and laminin-5. The affinity for laminin-5 however is much stronger. In hemidesmosomes it is found attached to laminin-5. The different alpha-6 splice variants do not influence the ligand specificities of the integrin. From studies with knockout mice it was found that in the absence of the integrin (beta-4 knockout or alpha-6 knockout) no hemidesmosomes were present, suggesting that the integrin is necessary for the formation or initiation of hemidesmosomes. these mice showed severe blistering of the skin and died soon after birth.

The alpha7/beta1 integrin is expressed on skeletal and cardiac muscle at specific stages during muscle development. It is a receptor for laminin-1 and binds to its E8 domain. This integrin is also found localized in focal contacts when melanoma cells attach to laminin-1, while normal melanocytes do not express this integrin. Since alpha7/beta1 is developmentally regulated in muscle cells, it is thought that this integrin has a role in their development. The expression of the three known splice variants is in addition developmentally regulated. Expression of alpha7B precedes the expression of alpha7A and alpha7C. Alpha7/beta1 is also a trophoblast specific laminin receptor on which it may serve a specific function during the early postimplantation period. This integrin is also known as VLA-7 (very late activation antigen 7).

Alpha8/beta1 is a receptor for fibronectin.

AlphaL/beta2 is a receptor for ICAM-1 to 3 (intercellular adhesion molecule 1 to 3). This integrin is only present on leukocytes and plays an important role in interactions between members of this family (e.g. B-cell to T-cell). AlphaL/beta2 is also involved in the interactions between cytotoxic cells and their target-cells. In addition, alphaL/beta2 is crucial for the invasion of leukocytes in tissues. ICAM-1 is

expressed on leukocytes and other cells, amongst them are endothelial cells, but only after they have been activated by cytokines for example which are produced in immune reactions and inflamed tissues. ICAM-2 is present on a lot of cells and does not change after cytokine activation. ICAM-3 is primarily expressed on resting

5 lymphocytes and plays a role in the onset of immune reactions. AlphaL/beta2 is normally not activated, but adhesion is induced by activation of the leukocyte, for example by PAF (platelet activating factor) which is produced in inflamed tissues. This integrin is also known as LFA-1 (leukocyte function associated antigen 1).

AlphaM/beta2 is a receptor for C3bi (inactivated form of C3b), factor X

10 (coagulation factor X), fibrinogen and ICAM-1 (intercellular adhesion molecule 1). It is expressed on monocytes, macrophages, NK cells and granulocytes. Alpha-M/beta-2 is important in adherence of monocytes and neutrophils to vascular endothelium, as well as in subsequent extravasation. It also plays a role in phagocytosis of complement coated particles. This integrin is also known as Mac-1 (macrophage receptor 1) and CR-3

15 (C3bi receptor).

AlphaV/beta1 is a receptor for fibronectin.

AlphaV/beta3 is a receptor for fibrinogen, fibronectin, von Willebrand's factor, Vitronectin, Tsp (Thrombospondin), osteopontin and Bsp1 (bone sialoprotein 1). It is expressed on endothelial cells, some B-cells, platelets and monocytes. alphaVb-

20 beta3 mediates platelet aggregation and endothelial cell adhesion to ECM proteins. This integrin is also known as VNR (vitronectin receptor).

Alphav/beta5 is a receptor for vitronectin. It is expressed on hepatoma cells, fibroblasts and carcinoma cells. This integrin is also known as alphav/betaS and alphav/beta3B.

25 Alphav/beta6 is a receptor for fibronectin. It is expressed on carcinoma cells.

AlphaX/beta2 is a receptor for fibrinogen. It is found on monocytes, macrophages, granulocytes, NK-cells and activated lymphocytes. This integrin is also known as p150 and CR-4 (C3bi receptor 4).

30 Alpha-IIb/beta3 is a receptor for fibrinogen, fibronectin, von Willebrand's factor and vitronectin. It is expressed on platelets. This integrin is also known as GPIIb-IIIa (glycoprotein IIb-IIIa on platelets).

As set forth above, a particular cell type can express predominantly only one or a subset of specific adhesion receptors. An adhesion receptor expression pattern can accordingly be determined for a particular cell type. Given a receptor expression profile for a particular cell in combination with knowledge of the receptor specificity of an adhesion modulatory peptide of the present invention, one can determine additional target cell types on which a particular adhesion modulatory peptide may act or can predict undesirable cross-reactivities (*e.g.*, adhering non-target cells within a cell population which inadvertently express the same or a similar receptor expression profile as a target cell).

### *Peptides and Peptide Analogs*

Table II sets forth preferred adhesion-modulatory peptides of the present invention.

15	**	TABLE II
20	Peptide	Function
	SDQDNNGKGSHE (SEQ ID NO:1)	Endothelial cell attachment
25	SDQDQDGDGHQDS (SEQ ID NO:2)	Endothelial cell attachment
	GRGDNPS (SEQ ID NO:3)	Fibronectin receptor binding; collagenase induction
	TPVVPTVDITYDGRGSLAY (SEQ ID NO:4)	$\beta$ integrin binding
30	TPVVPTVDITYDGRGD (SEQ ID NO:5)	Cell attachment
	DDDRKWGFC (SEQ ID NO:6)	Inhibits collagen interaction
35	DSVYGLRSK (SEQ ID NO:7)	Inhibits heparin binding
	LDSAS (SEQ ID NO:8)	Inhibits $\alpha$ 4 integrin binding
	SDV	Inhibits $\alpha$ 4 integrin binding
40	HDRKEFAKFEEERARA (SEQ ID NO:9)	$\beta$ 3 attachment

- 10 -

\*\* TABLE II (cont.)

5	Peptide	Function
10	DPGYIGSR (SEQ ID NO:10)	Endothelial cell (EC) attachment; Competes with EC attachment
	PNGRGESLAY (SEQ ID NO:11)	Inhibits fibroblast attachment; Inhibits collagenase induction
	DRYLKFRPV (SEQ ID NO:12)	Inhibits melanoma cell attachment
15	KGMNYTVR (SEQ ID NO:13)	neutrophils, endothelium, fibrosarcomas attachment melanoma attachment
20	KNNQKSEPLIGRKKT (SEQ ID NO:14)	heparin binding domain EGF-like motif competes with binding to glycosaminoglycans potential anti CD44(v3vx) activity
	VLEP (SEQ ID NO:15)	Inhibits VLA-4/VCAM interaction

25

The adhesion-modulatory peptides set forth in table II are described according to standard one-letter amino acid symbols. The following standard abbreviations are also used herein to identify amino acid residues.

30

TABLE III

35	Amino Acid	Three-letter Abbreviation	One-letter Symbol
	Alanine	Ala	A
	Arginine	Arg	R
	D-Arginine	D-Arg	dR
	Asparagine	Asn	N
40	Aspartic acid	Asp	D
	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glycine	Gly	G
45	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
50	Phenylalanine	Phe	F
	Proline	Pro	P

- 11 -

TABLE III (cont.)

5	Amino Acid	Three-letter Abbreviation	One-letter Symbol
10	Serine	Ser	S
	Threonine	Thr	T
	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valine	Val	V

15           The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the peptide. The use of naturally-occurring amino acids may be preferable to other hydrophobic moieties, for example, when coating prosthetic devices to be used in  
20 humans, because they are relatively non-immunogenic and non-toxic.

          It should be understood that a subject adhesion modulatory peptide need not include a core amino acid residue sequence which is identical to the amino acid residue sequence set forth in Table II, provided that the subject adhesion modulatory peptides retain the ability to specifically bind to a particular adhesion receptor or  
25 specifically inhibit binding to a particular adhesion receptor.

          Accordingly, an adhesion modulatory peptide of the present invention also includes any analog, fragment or chemical derivative of a peptide whose amino acid residue sequence is shown herein so long as the peptide retains the activity of the adhesion-modulatory peptide from which it is derived. Accordingly, an adhesion  
30 modulatory peptide can be subject to various changes, insertions, deletions and substitutions, either conservative or non-conservative, where such changes provide for certain advantages in its use or, at least, are not detrimental to its use.

          In this regard, an adhesion modulatory peptide of this invention corresponds to, rather than is identical to, one of the sequence set forth in Table II where  
35 one or more changes are made and it retains the ability to specifically bind to a particular adhesion receptor in one or more of the assays as defined herein.

The term "analog" includes any peptide having an amino acid residue sequence substantially identical to a sequence specifically shown herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the ability to specifically bind to a particular adhesion receptor or inhibit binding as described herein. Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.

The term "analog" also includes any peptide which is structurally similar to an adhesion modulatory peptide of the present invention but which has a chemically derivatized residue(s) and/or peptide linkage in place of a non-derivatized residue or linkage provided that such peptide displays the requisite activity (*e.g.*, functions in a substantially identical manner as the corresponding non-derivatized peptide). "Chemical derivative" refers, for example, to a subject polypeptide having one or more residues and/or linkages chemically derivatized according to routine methodology (*e.g.*, by reaction of a functional side group). The generation of such peptidomimetics may be achieved by techniques of modeling (*e.g.*, computerized molecular modeling) and chemical design known to those of skill in the art.

Such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be

substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.

Preferred modifications include, for example, modifications designed to enhance chemical stability, increase half-life, increase adsorption (*e.g.*, to an adhesion modulatory peptide-associated substrate), facilitate ease of purification, reduce cost of production, and the like. Particularly preferred modifications are those modifications designed to increase the stability of the adhesion modulatory peptide *in vivo*. Exemplary modifications are those that block susceptibility to proteolytic activity in biological fluids. Thus an adhesion modulatory peptide can have a stabilizing group at one or both termini. Typical stabilizing groups include amido (*e.g.*, at the C-terminus), acetyl (*e.g.*, at N-terminus), glycerol, benzyl, phenyl, tosyl, alkoxycarbonyl, alkyl carbonyl, benzyloxycarbonyl and the like end group modifications. Additional modifications include using a "L" amino acid in place of a "D" amino acid (*e.g.*, at the termini), cyclization of the polypeptide (*e.g.*, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide), and amide rather than amino or carboxy termini to inhibit exopeptidase activity.

Non-hydrolyzable peptide analogs can also be generated using benzodiazepine (see *e.g.*, Freidinger *et al.* in *Peptides: Chemistry and Biology*, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (see *e.g.*, Huffinan *et al.* in *Peptides: Chemistry and Biology*, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey *et al.* in *Peptides: Chemistry and Biology*, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson *et al.* (1986) *J. Med. Chem.* 29:295),  $\beta$ -turn dipeptide cores (Nagai *et al.* (1985) *Tetrahedron Lett.* 26:647; and Sato *et al.* (1986) *J. Chem. Soc. Perkin. Trans.* 1:1231), and  $\beta$ -aminoalcohols (Gordon *et al.* (1985) *Biochem. Biophys. Res. Commun.* 126:419; and Dann *et al.* (1986) *Biochem. Biophys. Res. Commun.* 134:71).

Natural peptide linkages can be replaced by a linkage selected from the group consisting of: --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>--CH<sub>2</sub>--, --CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>--, and --CH<sub>2</sub>SO--, by methods known in the art. A particularly preferred non-peptide linkage is --CH<sub>2</sub>NH--.

### Peptide Synthesis

The adhesion modulatory peptides of the present invention can be synthesized by any of the techniques that are known to one of ordinary skill in the art, for example, synthetic chemistry techniques (*e.g.* solid phase synthesis for solution  
5 synthesis) and/or recombinant DNA techniques. Synthetic chemistry techniques (*e.g.* solid phase synthesis) may be preferred for reasons of purity, freedom from undesired side products, and ease of product purification.

Briefly, the solid phase synthesis methods include the sequential addition of one or more amino acid residues or protected amino acid residues to a growing  
10 peptide chain. Normally, either the amino or carboxyl group of the first amino residue is protected by a suitable protecting group. A different protecting group can be used for amino acids containing a reactive side chain (*e.g.* lysine).

As a general first step, a protected first amino acid residue is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting  
15 group is then removed and a second amino acid residue in the sequence (suitably protected) is admixed and reacted under conditions suitable for forming an amide linkage with the first amino acid residue with the first amino acid residue attached to the solid support. The protecting group of the second amino acid residue is then removed and a third amino acid residue (likewise protected) is added, and so forth. After all of  
20 the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to afford the final peptide. Preferably, the linear sequence is synthesized using commercially available automated peptide synthesizers. The material so synthesized can be precipitated and further purified, for example by high performance  
25 liquid chromatography (HPLC). Although a purity of greater than 95 percent for the synthesized peptide is preferred, lower purity may be acceptable.

Alternatively, the peptides of the present invention can be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid having a sequence encoding such peptide. To produce a peptide by recombinant techniques, host  
30 cells (*e.g.*, bacterial cells such as *E. coli*, insect cells, yeast, or mammalian cells, for example, Chinese hamster ovary (CHO) cells) are transformed with a vector suitable for expressing a peptide of the invention and cultured in a medium such that the cells



produce the peptides. Peptides so-produced can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides including ultrafiltration, ion-exchange chromatography, gel filtration chromatography, electrophoresis or immunopurification with antibodies specific for the peptide.

5                   Accordingly, the present invention provides nucleic acid molecules which encode the peptides of the present invention, expression vectors and host cells suitable for expression of such peptides. Nucleic acid coding for the peptides of the invention can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci *et al.*, J. Am. Chem. Soc., 103:3185 (1981).

10                  Moreover, by chemically synthesizing the coding sequence, modifications can be made by substituting the appropriate bases for those encoding the native amino acid residue sequence.

                  Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook *et al. Molecular Cloning: A Laboratory*  
15   *Manual*, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art. Expression in mammalian, yeast or insect cells leads to partial or complete glycosylation of the recombinant material and formation of any inter- or intra-chain disulfide bonds. Suitable vectors for  
20   expression in yeast include YepSec1 (Baldari *et al.* (1987) *Embo J.* 6: 229-234); pMFa (Kurjan and Herskowitz (1982) *Cell* 30: 933-943); JRY88 (Schultz *et al.* (1987) *Gene* 54: 113-123) and pYES2 (Invitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and mammalian expression systems are also available. For example, a baculovirus system is commercially available (PharMingen, San Diego,  
25   CA) for expression in insect cells while the pMSG vector is commercially available (Pharmacia, Piscataway, NJ) for expression in mammalian cells.

                  For expression in *E. coli*, suitable expression vectors include, among others, pTRC (Amann *et al.* (1988) *Gene* 69: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRIT5 (Pharmacia,  
30   Piscataway, NJ); pET-11d (Novagen, Madison, WI) Jameel *et al.*, (1990) *J. Virol.* 64:3963-3966; and pSEM (Knapp *et al.* (1990) *BioTechniques* 8: 280-281). The use of pTRC, and pET-11d, for example, will lead to the expression of unfused protein. The

use of pMAL, pRIT5 pSEM and pGEX will lead to the expression of peptide fused to maltose E binding protein (pMAL), protein A (pRIT5), truncated  $\beta$ -galactosidase (PSEM), or glutathione S-transferase (pGEX). When a peptide of the invention is expressed as a fusion protein, it is particularly advantageous to introduce an enzymatic cleavage site at the fusion junction between the carrier protein and the peptide. The peptide may then be recovered from the fusion protein through enzymatic cleavage at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides. Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from, for example, Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA. The different vectors also have different promoter regions allowing constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann *et al.*, (1988) *supra*; pET-11d, Novagen, Madison, WI) or temperature induction (pRIT5, Pharmacia, Piscataway, NJ). It may also be appropriate to express recombinant peptides in different *E. coli* hosts that have an altered capacity to degrade recombinantly expressed proteins (*e.g.* U.S. patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic acid sequence to use codons preferentially utilized by *E. coli*, where such nucleic acid alteration would not affect the amino acid sequence of the expressed peptide.

Host cells can be transformed to express the nucleic acid sequences of the invention using conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming the host cells may be found in Sambrook *et al. supra*, and other laboratory textbooks. The nucleic acid sequences of the invention may also be chemically synthesized using standard techniques (*i.e.* solid phase synthesis).

The present invention also provides nucleic acid sequences encoding peptides of the invention. Nucleic acid sequences used in any embodiment of this invention can be cDNA obtained from cDNAs encoding the corresponding peptide sequences, or alternatively, can be any oligodeoxynucleotide sequence having all or a portion of a sequence represented herein, or their functional equivalents. Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques. A functional equivalent of an oligonucleotide sequence is one which

is 1) a sequence capable of hybridizing to a complementary oligonucleotide to which the sequence (or corresponding sequence portions) of the peptide, or fragments thereof, hybridizes, or 2) the sequence (or corresponding sequence portion) complementary to the nucleic acid sequences encoding the peptide sequence. Whether a functional  
5 equivalent must meet one or both criteria will depend on its use.

The present invention also provides a method of producing isolated adhesion modulatory peptides of the invention or portions thereof comprising the steps of culturing a host cell transformed with a nucleic acid sequence encoding an adhesion modulatory peptide of the invention in an appropriate medium to produce a mixture of  
10 cells and medium containing said adhesion modulatory peptide; and purifying the mixture to produce substantially pure adhesion modulatory peptide. Host cells transformed with an expression vector containing DNA coding for an adhesion modulatory peptide of the invention or a portion thereof are cultured in a suitable medium for the host cell. Adhesion modulatory peptides of the invention can be  
15 purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for the adhesion modulatory peptides or portions thereof of the invention.

20

### *Therapeutic Uses*

The adhesion modulatory peptides of the present invention were identified according to functional screening assays (*e.g.*, assays designed to screen test peptides for their ability to perform a desired biological function). Accordingly, the  
25 adhesion modulatory peptides of the present invention have general utility in promoting the adhesion of cells to, for example, physical substrates, molecular substrates, biomaterials (*e.g.*, reconstructive biomaterials) and prosthetic devices. In particular, the adhesion modulatory peptides of the present invention have the following utilities.

The adhesion modulatory peptides of the present invention (*e.g.*,  
30 endothelial cell adhesion modulatory peptides) have particular utility in promoting attachment of endothelial cells and further promote endothelial cell retention and spreading. Accordingly, the endothelial cell adhesion modulatory peptides of the

present invention have utility in improving endothelial cell adhesion to vascular graft surfaces. For instance, it is known that vascular grafts do not spontaneously endothelialize in humans. Accordingly, treatment of graft surfaces and/or synthetic graft materials (*e.g.*, polytetrafluoroethylene (“ePTFE”) or polyethylene terephthalate) with  
5 endothelial cell adhesion modulatory peptide prior to grafting can increase endothelial cell attachment as well as endothelial cell retention and spreading. Accordingly, the endothelial cell adhesion modulatory peptides of the present invention can be used in the regulation of vessel growth during wound healing and/or in the treatment of damage resulting from vascular disease.

10               The adhesion modulatory peptides of the present invention have further utility in inhibiting or preventing cellular apoptosis. For example, it is known that certain cells are dependent on adhesion or adherence to a substrate for survival (*e.g.*, adhesion-dependent cells). Accordingly, adhesion-enhancing peptides of the present invention can be used, for example, to prevent or inhibit cells from apoptosis (*e.g.*,  
15 rescue cells from matrix-induced programmed cell death) by providing cell-substrate contacts. Alternatively, the adhesion-inhibitory peptides of the present invention can be used to induce apoptosis in adhesion-dependent cells.

              The adhesion-modulatory peptides of the present invention further have utility in tissue engineering. Tissue engineering techniques involve culturing a variety  
20 of tissues both *in vitro* and *in vivo* using polymer “scaffolds” (*e.g.*, scaffolds made of biomaterials, for example, biodegradable materials) to support tissue growth. The adhesion modulatory peptides of the present invention can be used to stimulate and/or enhance cell attachment to such polymer scaffolds and concomitantly enhance tissue growth. Moreover, use of the cell adhesion modulatory peptides of the present invention  
25 to modify the surfaces of synthetic materials used in medical implants results in faster and more complete tissue integration as well as a reduction in foreign body response.

              The peptides of the present invention may be utilized for many *in vivo* medical uses such as coating of medical devices, including prostheses or implants, for example vascular implants, so as to facilitate the attachment of cells thereto.

Moreover, the adhesion-modulatory molecules of the present invention have specific activities which are based, at least in part, on their ability to bind or preferentially bind a specific adhesion receptor or particular cell type. Such specific activities are set forth below.

5                   Endothelial cell-specific adhesion peptides, also referred to as “endothelial cell attachment peptides” interact, in particular, with an EGF-like domain on an endothelial cell. For example, endothelial cell-specific adhesion peptides bind cells *via* heparan sulfate or ICAM molecules on the endothelial cell surface, as compared to binding the cell *via* an integrin. Such endothelial cell-specific adhesion  
10 peptides include, for example, SDQDNNGKGSHEs (SEQ ID NO:1) and SDQDQDGDGHQDS (SEQ ID NO:2).

Fibronectin receptor-binding peptides, for example, GRGDNPS (SEQ ID NO:3), ligate integrin receptors on the cell surface, upregulate metalloproteases (*e.g.*, collagenase I) which are specific to remodelling systems (as contrasted with general  
15 destructive enzymes). Accordingly, such peptides are useful in the treatment of fibrosis (*e.g.*, chondrofibrosis), in particular, in the clearing of debris.

Adhesion-modulatory peptides, for example, the peptide TPVVPTVDITYDGRGD (SEQ ID NO:5) are specific for  $\alpha v \beta 3$  integrin expressing cells (*e.g.*, activated macrophages, and regenerating endothelial cells) and, in particular, have  
20 utility during vascularization.

Adhesion-modulatory peptides, for example, DDDRKWGFC (SEQ ID NO:6) inhibit cell binding to collagen (*via* the  $\beta 1$  subunit of integrins). During wound healing, recruited fibroblasts transiently differentiate into myofibroblasts, which express  $\alpha 2 \beta 1$  integrins, (the  $\alpha 2$  integrin subunit being responsible for actin binding).  
25 Accordingly, myofibroblasts bind both collagen at the wound site and actin, resulting in wound contraction, as well as wrinkling and scarring. Accordingly, peptides which specifically inhibit at least the collagen binding of such cells, can minimize wound contraction, resulting in reduced keloid tissue formation and scarring.

Adhesion-modulatory peptides, for example DSVVYGLRSK (SEQ ID NO:6) inhibit the binding of heparin to proteins or cell binding to glycosaminoglycans and accordingly, have potential utility as anticlotting agents.  
30

Adhesion-modulatory peptides, for example, LDSAS (SEQ ID NO:8) and SDV specifically inhibit  $\alpha 4$  integrin binding.  $\alpha 4$  has been demonstrated to be important, for example, in cell migration through vessels. Accordingly, such adhesion modulatory peptides may have immunomodulatory effects and/or anti-cancer effects.

5 Adhesion-modulatory peptides, for example, DPGYIGSR (SEQ ID NO:10), inhibit endothelial cell attachment, in particular by competing for  $\alpha v \beta 3$  integrin binding on the cell surface. Accordingly, such peptides may have utility as anti-angiogenic factors.

10 Adhesion-modulatory peptides, for example, KNNQKSEPLIGRKKT (SEQ ID NO:14) include an EGF-like motif which specifically competes with binding of cells to glycosaminoglycans. In particular, such peptides have anti-CD44 (v3vx) activity and have potential use as anti-tumorigenic agents.

15 Adhesion-modulatory peptides, for example, DRYLKFRPV (SEQ ID NO:12) specifically inhibit melanoma cell attachment. Melanoma cells, in particular, have a distinct receptor expression profile (*e.g.*, a low integrin variable profile). Accordingly, such peptides can be used to sequester melanoma cells, by forming a physical barrier of peptide-associated substrate around a melanoma, thereby preventing its metastasis.

20 Adhesion-modulatory peptides, for example, PNGRGESLAY (SEQ ID NO:11) can function as RGD analogs (*e.g.*, by binding integrins), and accordingly may have antithrictic activity (*e.g.*, a dis-integrin activity).

25 Adhesion-modulatory molecules, for example, KGMNYTVR (SEQ ID NO:13) adhere neutrophils and accordingly may have an anti-bacterial or bacteriocidal effect.

### *Therapeutic Compositions and Preparations*

The present invention provides therapeutic compositions comprising isolated peptides or analogs thereof and a pharmaceutically acceptable carrier, or diluent. Administration of the therapeutic compositions of the present invention to  
30 an individual can be carried out using known techniques. Peptides or analogs thereof may be administered to an individual in combination with, for example, an appropriate diluent, adjuvant and/or a carrier. Pharmaceutically acceptable diluents

include saline and aqueous buffer solutions. Pharmaceutically acceptable carriers include polyethylene glycol (Wie *et al.* (1981) *Int. Arch. Allergy Appl. Immunol.* 64:84-99) and liposomes (Strejan *et al.* (1984) *J. Neuroimmunol* 7: 27). The carrier can also include a matrix, *e.g.*, fibrin, collagen, gelatin, agarose, calcium phosphate  
5 containing compounds and combinations thereof. Adjuvant is used in its broadest sense and includes any immune stimulating compound such as interferon. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.

Administration of the therapeutic compositions of the present  
10 invention to an individual can be carried out using known procedures at dosages and for periods of time effective to significantly reduce or eliminate symptoms associated with the condition or disease being treated. Effective amounts of the therapeutic compositions will vary according to the age, sex, and weight of the "subject", and the ability of the peptide to perform its intended function. The term  
15 "subject" is intended to include subjects susceptible to the particular condition or disease being treated. The term "subject" is intended to include mammals, particularly humans.

In addition to compositions containing a single peptide, mixtures of at least two peptides (*i.e.*, a physical mixture of at least two peptides) can also be  
20 provided. Such compositions can be administered in the form of a therapeutic composition with a pharmaceutically acceptable carrier or diluent. A therapeutically effective amount of one or more of such compositions can be administered simultaneously or sequentially. Preferred therapeutic compositions comprise peptides which include the peptides having the amino acid sequences  
25 shown in SEQ ID NOs:1-15. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A therapeutically effective amount is that amount sufficient to significantly reduce or alleviate symptoms associated with the  
30 particular condition or disease being treated. A preferred composition of the present invention is a wound healing composition. The wound healing composition

contains a wound healing effective amount of adhesion-modulatory peptide of the invention.

The peptide or analog thereof may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, 5 inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active compound may be coated within a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

To administer a peptide by other than parenteral administration, it may be 10 necessary to coat the peptide with, or co-administer the peptide with, a material to prevent its inactivation. For example, peptide may be co-administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan *et al.*, (1984) *J.* 15 *Neuroimmunol.* 7:27).

The peptide or analog may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

20 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved 25 against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of 30 the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid,



thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol and sorbitol or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about, including in the composition, an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating active compound (*i.e.*, peptide or fragment thereof) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (*i.e.*, peptide or fragment thereof) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

When a peptide of the invention is suitably protected, as described above, the peptide may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The peptide and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the peptide may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of peptide. The percentage of the composition and preparations may, of course, be varied and may conveniently be between about 5 to 80% of the weight of the unit. The amount of peptide in such therapeutically useful compositions is such that a suitable dosage will be obtained.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may

contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservative, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the peptide or analog may be incorporated into sustained-release preparations and formulations.

10               The peptide or analog may also be administered topically. The use of a non-aqueous lipid miscible carrier, for example, such as prepared with liposomes are particularly advantageous since they provide improved activity at the treatment site (*e.g.*, the wound site).

15               The language "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can  
20 also be incorporated into the compositions.

              It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. The language "dosage unit form" includes physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of  
25 active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the peptide or analog and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such a peptide or analog for the treatment  
30 of sensitivity in individuals.

- 25 -

Appropriate dosages of the peptides of the invention will depend upon the condition presented by the individual subject. The skilled medical worker will be able to determine appropriate dosages required to combat the physiological activity. However, in general, amounts of from about 1 $\mu$ g to 100 $\mu$ g/kg body weight/day of the  
5 biologically active peptide should be useful.

The entire contents of all of the references (including literature references, issued patents, and published patent applications) cited throughout this application are hereby expressly incorporated by reference.

- 26 -

We claim:

1. A method of modulating adhesion of a target cell to a substrate, comprising providing the target cell with an adhesion modulatory peptide-associated substrate such that adhesion of the target cell to the substrate is modulated.
2. The method of claim 1, wherein the adhesion modulatory peptide comprises a peptide which specifically enhances adhesion of the target cell.
3. The method of claim 1, wherein the adhesion modulatory peptide comprises a peptide which specifically inhibits adhesion of the target cell
4. The method of claim 1, wherein the adhesion modulatory peptide is selected from the group consisting of an endothelial cell adhesion modulatory peptide, a fibroblast adhesion modulatory peptide and a macrophage adhesion modulatory peptide.
5. The method of claim 4, wherein the adhesion modulatory peptide is an endothelial cell adhesion modulatory peptide.
6. The method of claim 4, wherein the adhesion modulatory peptide is a fibroblast adhesion modulatory peptide.
7. The method of claim 4, wherein the adhesion modulatory peptide is a neutrophil adhesion modulatory peptide or a myofibroblast adhesion modulatory peptide.
8. The method of claim 1, wherein the adhesion modulatory peptide comprises an amino acid residue sequence selected from the group consisting of SDQDNNGKGSHEs (SEQ ID NO:1), SDQDQDGDGHQDS (SEQ ID NO:2), GRGDNPS (SEQ ID NO:3), TPVVPTVDTYDGRGDSLAY (SEQ ID NO:4), TPVVPTVDTYDGRGD (SEQ ID NO:5), HDRKEFAKFEEERARA (SEQ ID

NO:10), DPGYIGSR (SEQ ID NO:10), KGMNYTVR (SEQ ID NO:13), and VLEP (SEQ ID NO:15).

9. The method of claim 1, wherein the adhesion modulatory peptide  
5 comprises an amino acid residue sequence selected from the group consisting of  
DDDRKWGFC (SEQ ID NO:6), DSVVYGLRSK (SEQ ID NO:7), LDSAS (SEQ ID  
NO:8), SDV (SEQ ID NO:9), PNGRGESLAY (SEQ ID NO:11), and DRYLKFRPV  
(SEQ ID NO:12).
10. The method of claim 1, wherein the adhesion modulatory  
10 molecule enhances binding of an adhesion receptor predominantly expressed by the  
target cell.
11. The method of claim 1, wherein the adhesion modulatory  
15 molecule inhibits binding of an adhesion receptor predominantly expressed by the target  
cell.
12. The method of claim 1, wherein the target cell is selected from the  
group consisting of an endothelial cell, a fibroblast and a macrophage.
- 20 13. The method of claim 12, wherein the target cell is an endothelial  
cell.
14. The method of claim 12, wherein the target cell is a fibroblast.
- 25 15. The method of claim 1, wherein the target cell is a neutrophil or a  
myofibroblast.
16. The method of claim 1, wherein the target cell is within a cell  
30 population.
17. The method of claim 1, wherein the target cell is within a subject.

18. The method of claim 1, wherein the substrate is selected from the group consisting of a polyvinyl surface, a gel, collagen, hyaluronic acid, titanium and  
5 PGA.

19. The method of claim 1, further comprising contacting the substrate with the adhesion modulatory peptide, forming the adhesion modulatory peptide-associated substrate prior to providing the cell with the substrate.  
10

20. An adhesion modulatory peptide which modulates adhesion of a target cell to a substrate.

21. The adhesion modulatory peptide of claim 20, wherein the  
15 peptide enhances adhesion of a target cell to a substrate.

21. The adhesion modulatory peptide of claim 20, wherein the peptide inhibits adhesion of a target cell to a substrate.

22. The adhesion modulatory peptide of claim 20, comprising an amino acid residue sequence selected from the group consisting of  
SDQDNNGKGSHEs (SEQ ID NO:1), SDQDQDGDGHQDS (SEQ ID NO:2),  
GRGDNPS (SEQ ID NO:3), TPVVPTVDTYDGRGDSLAY (SEQ ID NO:4),  
TPVVPTVDTYDGRGD (SEQ ID NO:5), HDRKEFAKFEEERARA (SEQ ID NO:9),  
25 DPGYIGSR (SEQ ID NO:10), KGMNYTVR (SEQ ID NO:13) and VLEP (SEQ ID NO:15).

23. The adhesion modulatory peptide of claim 20, comprising an amino acid residue sequence selected from the group consisting of DDRKKGFC  
30 (SEQ ID NO:6), DSVVYGLRSK (SEQ ID NO:7), LDSAS (SEQ ID NO:8), SDV (SEQ ID NO:9), PNGRGESLAY (SEQ ID NO:12), and DRYLKFRPV (SEQ ID NO:13).

- 29 -

24. The adhesion modulatory peptide of claim 20 having a molecular weight less than about 2500 Da.

26. A substrate treated with the adhesion modulatory peptide of claim  
5 20.

25. A device treated with the adhesion modulatory peptide of claim  
20.

10 26. A composition comprising the adhesion modulatory peptide of claim 20 and a carrier suitable for *in vivo* use.

27. A device for modulation of adhesion of a target cell comprising a substrate in combination with an adhesion-modulatory peptide, forming a device for  
15 modulating adhesion.

## SEQUENCE LISTING

<110> Children's Medical Center Corporation et al.

<120> Adhesion Modulatory Peptides and Methods for Use

<130> CMZ-124CPPC

<140>

<141>

<150> 60/129,709

<151> 1999-04-16

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 1

Ser Asp Gln Asp Asn Asn Gly Lys Gly Ser His Glu Ser  
1 5 10

<210> 2

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 2

Ser Asp Gln Asp Gln Asp Gly Asp Gly His Gln Asp Ser  
1 5 10

<210> 3

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 3

Gly Arg Gly Asp Asn Pro Ser  
1 5



<210> 4  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 4  
Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly Asp Ser  
1 5 10 15

Leu Ala Tyr

<210> 5  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 5  
Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly Asp  
1 5 10 15

<210> 6  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 6  
Asp Asp Asp Arg Lys Trp Gly Phe Cys  
1 5

<210> 7  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 7  
Asp Ser Val Val Tyr Gly Leu Arg Ser Lys  
1 5 10

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 8  
Leu Asp Ser Ala Ser  
1 5

<210> 9  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 9  
His Asp Arg Lys Glu Phe Ala Lys Phe Glu Glu Glu Arg Ala Arg Ala  
1 5 10 15

<210> 10  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 10  
Asp Pro Gly Tyr Ile Gly Ser Arg  
1 5

<210> 11  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 11  
Pro Asn Gly Arg Gly Glu Ser Leu Ala Tyr  
1 5 10

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 12  
Asp Arg Tyr Leu Lys Phe Arg Pro Val  
1 5

<210> 13  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 13  
Lys Gly Met Asn Tyr Thr Val Arg  
1 5

<210> 14  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 14  
Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr  
1 5 10 15

<210> 15  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
peptide

<400> 15  
Val Leu Glu Pro  
1

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 October 2000 (26.10.2000)

PCT

(10) International Publication Number  
**WO 00/63236 A3**

- (51) International Patent Classification<sup>7</sup>: C07K 7/04, 5/08, A61K 38/06, 38/08
- (21) International Application Number: PCT/US00/10329
- (22) International Filing Date: 17 April 2000 (17.04.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/129,709 16 April 1999 (16.04.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/129,709 (CIP)  
Filed on 16 April 1999 (16.04.1999)
- (71) Applicant (for all designated States except US): **CHILDREN'S MEDICAL CENTER CORPORATION** [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **ASHKAR, Samy** [LB/US]; Apartment 606, 12 Stoneholm Street, Boston, MA 02115 (US).
- (74) Agents: **HANLEY, Elizabeth, A.** et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— With international search report.
- (88) Date of publication of the international search report:  
28 June 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ADHESION MODULATORY PEPTIDES AND METHODS FOR USE

(57) Abstract: The invention provides methods for modulating cell adhesion. The invention also provides novel adhesion modulatory peptides, substrates coated with such adhesion modulatory peptides and devices for modulation of target cell adhesion.

WO 00/63236 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/10329

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K7/04 C07K5/08 A61K38/06 A61K38/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, STRAND, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 08730 A (CHILDRENS MEDICAL CENTER) 25 February 1999 (1999-02-25)  page 2, paragraph 1; claim 19 ---	1-8, 10-22, 24-27
A	WO 98 16241 A (LIU XUE YAN ;HAWIGER JACK J (US); TIMMONS SHEILA (US); UNIV VANDER) 23 April 1998 (1998-04-23) page 45; figure 1 ---	1-8, 10-22, 24-27
A	EP 0 278 781 A (US GOVERNMENT) 17 August 1988 (1988-08-17)  page 10, paragraph 1; claims 1,10 page 1, line 38 ---  -/--	1-8, 10-22, 24-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 December 2000

Date of mailing of the international search report

10.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Deffner, C-A

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/10329

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 13692 A (UNIV MINNESOTA ;US OF AMERICA AS REPRESENTED (US)) 23 June 1994 (1994-06-23) claims 1,7 ---	1-8, 10-22, 24-27
A	WO 89 01493 A (UNIV MINNESOTA) 23 February 1989 (1989-02-23)  page 5; claim 1 page 9, line 24 - line 34 ---	1-8, 10-22, 24-27
A	WO 92 06115 A (SCHERING CORP) 16 April 1992 (1992-04-16) see sequence no 2 ---	8
X	A.LDBERG ET AL.: "COMP (Cartilage Oligomeric Matrix Protein) Is Structurally Related to the Thrombospondins" J.BIOL.CHEM., vol. 267, no. 31, 1992, pages 22346-50, XP002150026 figure 1 ---	8
X	WO 89 07613 A (DANA FARBER CANCER INST INC) 24 August 1989 (1989-08-24)  figure 2B ---	1-8, 10-22, 24-27
A	WO 92 02544 A (INST NAT SANTE RECH MED) 20 February 1992 (1992-02-20)  claim 3 -----	1-8, 10-22, 24-27

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/10329

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-8,10-22,24-27 in as far as sequences no. 1 and 2 are concerned, methods,  
sequences devices and compositions concerning sequences no. 1 and 2
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 1 is concerned.

2. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 2 is concerned.

3. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 3 is concerned

4. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequences no 4 and 5 are concerned.

5. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 9 (HDRKEFAKFEEERARA, according to Table II) is concerned.

6. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 10 (DPGYIGSR) is concerned.

7. Claims: Claims 1- 8, 10- 22, 24- 27 partially

Claims 1- 8, 10- 22, 24- 27 partially method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 13 is concerned.

8. Claims: Claims 1- 8, 10- 22, 24- 27 partially



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims 1- 8, 10- 22, 24- 27 partially method, for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 15 is concerned.

9. Claims: Claims 1- 7, 9- 21, 23- 27 partially

Claims 1- 7, 9- 21, 23- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 6 is concerned.

10. Claims: Claims 1- 7, 9- 21, 23- 27 partially

Claims 1- 7, 9- 21, 23- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 7 is concerned.

11. Claims: Claims 1- 7, 9- 21, 23- 27 partially

Claims 1- 7, 9- 21, 23- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 8 is concerned.

12. Claims: Claims 1- 7, 9- 21, 23- 27 partially

Claims 1- 7, 9- 21, 23- 27 partially method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence SDV (indicated in original claim 9 as seq. 9) is concerned.

13. Claims: Claims 1- 7, 9- 21, 23- 27 partially

Claims 1- 7, 9- 21, 23- 27 partially, method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 11 is concerned.

14. Claims: Claims 1- 7, 9- 21, 23- 27 partially

Claims 1- 7, 9- 21, 23- 27 partially method for modulation of cell adhesion and peptide sequence, device and composition in as far as sequence no 12 is concerned.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/10329

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9908730	A	25-02-1999	AU 8783798 A EP 1003570 A	08-03-1999 31-05-2000
WO 9816241	A	23-04-1998	AU 4815397 A	11-05-1998
EP 0278781	A	17-08-1988	AT 96806 T AU 600112 B AU 1394588 A CA 1329446 A DE 3885313 D DE 3885313 T IL 85372 A WO 8806039 A US 5092885 A	15-11-1993 02-08-1990 14-09-1988 10-05-1994 09-12-1993 03-03-1994 01-12-1992 25-08-1988 03-03-1992
WO 9413692	A	23-06-1994	US 5591719 A EP 0673384 A SG 49017 A US 5840691 A	07-01-1997 27-09-1995 18-05-1998 24-11-1998
WO 8901493	A	23-02-1989	US 4870160 A AT 84796 T DE 3877765 A DE 3877765 D DE 3877765 T EP 0379511 A JP 3501251 T	26-09-1989 15-02-1993 04-03-1993 04-03-1993 19-08-1993 01-08-1990 22-03-1991
WO 9206115	A	16-04-1992	AT 132162 T AU 664540 B AU 8742991 A CA 2092541 A DE 69115917 D DE 69115917 T EP 0550650 A HU 67708 A NZ 239954 A US 5451658 A ZA 9107669 A	15-01-1996 23-11-1995 28-04-1992 28-03-1992 08-02-1996 23-05-1996 14-07-1993 28-04-1995 24-02-1995 19-09-1995 26-08-1992
WO 8907613	A	24-08-1989	US 5049659 A AU 628806 B AU 3192989 A DK 189090 A EP 0406257 A JP 3502453 T US 5238839 A	17-09-1991 24-09-1992 06-09-1989 08-10-1990 09-01-1991 06-06-1991 24-08-1993
WO 9202544	A	20-02-1992	FR 2665703 A EP 0542899 A	14-02-1992 26-05-1993